Lucid Diagnostics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Lucid Diagnostics Inc. (LUCD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.45 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-12
- Lucid Diagnostics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 220.00K shares, a 137.84% increase year-over-year.
- Lucid Diagnostics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 2.23M shares, a 61.66% increase year-over-year.
- Lucid Diagnostics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 530.00K shares, a 310.85% increase year-over-year.
- Lucid Diagnostics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 295.00K shares, a 247.06% increase year-over-year.
- Lucid Diagnostics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.30M shares, a 38.49% decline from fiscal 2024.
- Lucid Diagnostics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.73M shares, a 3.18% increase from fiscal 2023.
- Lucid Diagnostics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 3.62M shares, a 52.98% increase from fiscal 2022.
- Lucid Diagnostics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.37M shares, a 11725.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 220.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 2.45M shares 10-Q · filed 2026-08-12 | 2.98M shares derived: sum of 3 quarters · filed 2026-08-12 | 3.27M shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 2.23M shares 10-Q · filed 2026-05-13 | 2.76M shares derived: sum of 2 quarters · filed 2026-05-13 | 3.05M shares derived: sum of 3 quarters · filed 2026-05-13 | 3.15M shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 530.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | 825.00K shares derived: sum of 2 quarters · filed 2026-03-25 | 917.50K shares derived: sum of 3 quarters · filed 2026-03-25 | 2.30M shares 10-K · filed 2026-03-25 |
| 2025-09-30 | 295.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 387.50K shares derived: sum of 2 quarters · filed 2025-11-12 | 1.77M shares 10-Q · filed 2025-11-12 | 1.90M shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-06-30 | 92.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 1.47M shares 10-Q · filed 2025-08-12 | 1.60M shares derived: sum of 3 quarters · filed 2026-03-25 | 1.69M shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-03-31 | 1.38M shares 10-Q · filed 2025-05-13 | 1.51M shares derived: sum of 2 quarters · filed 2026-03-25 | 1.59M shares derived: sum of 3 quarters · filed 2026-03-25 | 2.11M shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-12-31 | 129.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | 214.00K shares derived: sum of 2 quarters · filed 2026-03-25 | 733.00K shares derived: sum of 3 quarters · filed 2026-03-25 | 3.73M shares 10-K · filed 2026-03-25 |
| 2024-09-30 | 85.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 604.00K shares derived: sum of 2 quarters · filed 2024-11-12 | 3.60M shares 10-Q · filed 2024-11-12 | 4.24M shares derived: sum of 4 quarters · filed 2025-03-24 |
| 2024-06-30 | 519.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 3.52M shares 10-Q · filed 2024-08-12 | 4.15M shares derived: sum of 3 quarters · filed 2025-03-24 | |
| 2024-03-31 | 3.00M shares 10-Q · filed 2024-05-13 | 3.64M shares derived: sum of 2 quarters · filed 2025-03-24 | ||
| 2023-12-31 | 635.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | 3.62M shares 10-K · filed 2025-03-24 | ||
| 2023-09-30 | 2.98M shares 10-Q · filed 2023-11-13 | |||
| 2022-12-31 | 2.37M shares 10-K · filed 2024-03-25 | |||
| 2022-06-30 | 347.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 2.11M shares 10-Q · filed 2022-08-15 | ||
| 2022-03-31 | 1.76M shares 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | 20.00K shares 10-K · filed 2022-04-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| Apyx Medical Corp (APYX) | United States | $0.120B | -21.85 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |